Answers are grounded in this paper and cite their sources.
Retrospective study compares treatment efficacy and safety in ocular cysticercosis patients, highlighting six-week regimen benefits.
Background: To compare the efficacy and safety of four-week and six-week treatment regimens for ocular cysticercosis. Method: This was a retrospective study where medical records of patients diagnosed with peri-ocular cysticercosis from January 2018 to March 2025 at a tertiary eye care centre in North India were reviewed. Patients who were treated using albendazole and steroids with either four-week or six-week regimen were included. The primary outcome measures were cyst resolution as assessed by B-scan, symptomatic relief which was assessed by improvement in amount of ptosis , ocular motility, and diplopia grade at follow-up, and secondary outcome measures were safety and recurrence. Result: Eighty-three patients were included in the study with 44 patients in the four-week group and 39 patients in the six-week group. Both groups showed marked clinical improvement, with 100% regression of ptosis, complete improvement of extraocular movement restriction, and cyst collapse on B-scan in all patients. However, residual diplopia in extreme gaze persisted in 56% of the four-week regimen ( P = 0.55), whereas the six-week regimen achieved 84% complete remission ( P = 0.045). Both regimens were well tolerated. Conclusion: Both four-week and six-week regimens are effective in managing peri-ocular cysticercosis. However, the six-week regimen is more beneficial in controlling residual diplopia, even in extreme gaze. The duration of treatment should be tailored as per severity of symptoms and functional impact.
No takes yet. Share an insight, caveat, or question.
Aishwarya et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: